This database contains 34 studies, archived under the term: "for"
Click here to filter this large number of results.
The Peaceful Mind program: A pilot test of a cognitive–behavioral therapy–based intervention for anxious patients with Dementia
Stanley, Melinda A.,
Calleo, Jessica,
Bush, Amber L.,
Wilson, Nancy,
Snow, A. Lynn,
Kraus-Schuman, Cynthia,
Paukert, Amber L.,
Petersen, Nancy J.,
Brenes, Gretchen A.,
Schulz, Paul E.,
Williams, Susan P.,
Kunik, Mark E.
Objectives: To assess feasibility and to conduct a preliminary evaluation of outcomes following Peaceful Mind, a cognitive-behavioral therapy-based intervention for anxiety in dementia, relative to usual care. Design: Pilot randomized controlled trial including assessments at baseline and 3 and 6 months. Setting: Houston, TX. Participants: Thirty-two outpatients diagnosed with mild (47%) or moderate (53%) dementia […]
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease
Sabbagh, Marwan N.,
Agro, Albert,
Bell, Joanne,
Aisen, Paul S,
Schweizer, Edward,
Galasko, Douglas
Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.; Methods: Patients aged 50 years and older who met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer […]
Home blood pressure measurement in elderly patients with cognitive impairment: comparison of agreement between relative-measured blood pressure and automated blood pressure measurement
Plichart, Matthieu,
Seux, Marie-Laure,
Caillard, Laure,
Chaussade, Edouard,
Vidal, Jean-Sébastien,
Boully, Clémence,
Hanon, Olivier
Objectives: Home blood pressure measurement (HBPM) is recommended by guidelines for hypertension management. However, this method might be difficult to use in elderly individuals with cognitive disorders. Our aim was to assess the agreement and the feasibility of HBPM by a relative as compared with 24-h ambulatory blood pressure monitoring (ABPM) in elderly patients with […]
Technology-based orientation programs to support indoor travel by persons with moderate Alzheimer’s disease: impact assessment and social validation
Lancioni, Giulio E.,
Perilli, Viviana,
O’Reilly, Mark F.,
Singh, Nirbhay N.,
Sigafoos, Jeff,
Bosco, Andrea,
Caffò, Alessandro O.,
Picucci, Luciana,
Cassano, Germana,
Groeneweg, Jop
The present study (a) extended the assessment of an orientation program involving auditory cues (i.e., verbal messages automatically presented from the destinations) with five patients with Alzheimer’s disease, (b) compared the effects of this program with those of a program with light cues (i.e., a program in which strobe lights were used instead of the […]
Problem adaptation therapy for older adults with major depression and cognitive impairment: A randomized clinical trial
Kiosses, Dimitris N.,
Ravdin, Lisa D.,
Gross, James J.,
Raue, Patrick,
Kotbi, Nabil,
Alexopoulos, George S.
IMPORTANCE: Problem adaptation therapy (PATH) is a treatment for older adults with major depression, cognitive impairment (from mild cognitive deficits to moderate dementia), and disability. Antidepressants have limited efficacy in this population and psychosocial interventions are inadequately investigated. OBJECTIVE: To test the efficacy of 12-week PATH vs supportive therapy for cognitively impaired patients (ST-CI) in […]
Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use
Jacobs, Emily G.,
Kroenke, Candyce,
Lin, Jue,
Epel, Elissa S.,
Kenna, Heather A.,
Blackburn, Elizabeth H.,
Rasgon, Natalie L.
Apolipoprotein-ε4 (APOE-ε4) is a major genetic risk factor for cognitive decline, Alzheimer’s disease (AD) and early mortality. An accelerated rate of biological aging could contribute to this increased risk. Here, we determined whether APOE-ε4 status impacts leukocyte telomere length (TL) and the rate of cellular senescence in healthy mid-life women and, further, whether hormone replacement […]
Memantine effects measured with the Relevant Outcome Scale for Alzheimer’s disease in an open-label, single-arm, multicenter clinical study
Holthoff, Vjera,
Ferris, Steven,
Gauthier, Serge,
Ihl, Ralf,
Robert, Philippe,
Winblad, Bengt,
Sternberg, Kati,
Tennigkeit, Frank
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) […]